Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Targeting the pedunculopontine nucleus in Parkinson's disease: Time to go back to the drawing board.

Albin RL, Surmeier DJ, Tubert C, Sarter M, Müller MLTM, Bohnen NI, Dauer WT.

Mov Disord. 2018 Nov 6. doi: 10.1002/mds.27540. [Epub ahead of print] No abstract available.

PMID:
30398673
2.

Regional vesicular acetylcholine transporter distribution in human brain: A [18 F]fluoroethoxybenzovesamicol positron emission tomography study.

Albin RL, Bohnen NI, Muller MLTM, Dauer WT, Sarter M, Frey KA, Koeppe RA.

J Comp Neurol. 2018 Sep 26. doi: 10.1002/cne.24541. [Epub ahead of print]

PMID:
30255936
3.

A cell autonomous torsinA requirement for cholinergic neuron survival and motor control.

Pappas SS, Li J, LeWitt TM, Kim JK, Monani UR, Dauer WT.

Elife. 2018 Aug 17;7. pii: e36691. doi: 10.7554/eLife.36691.

4.

Model-based and Model-free Machine Learning Techniques for Diagnostic Prediction and Classification of Clinical Outcomes in Parkinson's Disease.

Gao C, Sun H, Wang T, Tang M, Bohnen NI, Müller MLTM, Herman T, Giladi N, Kalinin A, Spino C, Dauer W, Hausdorff JM, Dinov ID.

Sci Rep. 2018 May 8;8(1):7129. doi: 10.1038/s41598-018-24783-4.

5.

A motif within the armadillo repeat of Parkinson's-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway.

Antoniou N, Vlachakis D, Memou A, Leandrou E, Valkimadi PE, Melachroinou K, Re DB, Przedborski S, Dauer WT, Stefanis L, Rideout HJ.

Sci Rep. 2018 Feb 22;8(1):3455. doi: 10.1038/s41598-018-21931-8.

6.

Inherited dystonias: clinical features and molecular pathways.

Weisheit CE, Pappas SS, Dauer WT.

Handb Clin Neurol. 2018;147:241-254. doi: 10.1016/B978-0-444-63233-3.00016-6. Review.

PMID:
29325615
7.

TorsinA dysfunction causes persistent neuronal nuclear pore defects.

Pappas SS, Liang CC, Kim S, Rivera CO, Dauer WT.

Hum Mol Genet. 2018 Feb 1;27(3):407-420. doi: 10.1093/hmg/ddx405.

PMID:
29186574
8.

The DYT6 Dystonia Protein THAP1 Regulates Myelination within the Oligodendrocyte Lineage.

Yellajoshyula D, Liang CC, Pappas SS, Penati S, Yang A, Mecano R, Kumaran R, Jou S, Cookson MR, Dauer WT.

Dev Cell. 2017 Jul 10;42(1):52-67.e4. doi: 10.1016/j.devcel.2017.06.009.

9.

Forebrain knock-out of torsinA reduces striatal free-water and impairs whole-brain functional connectivity in a symptomatic mouse model of DYT1 dystonia.

DeSimone JC, Pappas SS, Febo M, Burciu RG, Shukla P, Colon-Perez LM, Dauer WT, Vaillancourt DE.

Neurobiol Dis. 2017 Oct;106:124-132. doi: 10.1016/j.nbd.2017.06.015. Epub 2017 Jul 1.

10.

TorsinA controls TAN line assembly and the retrograde flow of dorsal perinuclear actin cables during rearward nuclear movement.

Saunders CA, Harris NJ, Willey PT, Woolums BM, Wang Y, McQuown AJ, Schoenhofen A, Worman HJ, Dauer WT, Gundersen GG, Luxton GW.

J Cell Biol. 2017 Mar 6;216(3):657-674. doi: 10.1083/jcb.201507113. Epub 2017 Feb 27.

11.

Eighth International Chorea-Acanthocytosis Symposium: Summary of Workshop Discussion and Action Points.

Pappas SS, Bonifacino J, Danek A, Dauer WT, De M, De Franceschi L, DiPaolo G, Fuller R, Haucke V, Hermann A, Kornmann B, Landwehrmeyer B, Levin J, Neiman AM, Rudnicki DD, Sibon O, Velayos-Baeza A, Vonk JJ, Walker RH, Weisman LS, Albin RL.

Tremor Other Hyperkinet Mov (N Y). 2017 Feb 15;7:428. doi: 10.7916/D8XD127W. eCollection 2017.

12.

Lamina-associated polypeptide 1 is dispensable for embryonic myogenesis but required for postnatal skeletal muscle growth.

Shin JY, Méndez-López I, Hong M, Wang Y, Tanji K, Wu W, Shugol L, Krauss RS, Dauer WT, Worman HJ.

Hum Mol Genet. 2017 Jan 1;26(1):65-78. doi: 10.1093/hmg/ddw368.

13.

Current Opinions and Areas of Consensus on the Role of the Cerebellum in Dystonia.

Shakkottai VG, Batla A, Bhatia K, Dauer WT, Dresel C, Niethammer M, Eidelberg D, Raike RS, Smith Y, Jinnah HA, Hess EJ, Meunier S, Hallett M, Fremont R, Khodakhah K, LeDoux MS, Popa T, Gallea C, Lehericy S, Bostan AC, Strick PL.

Cerebellum. 2017 Apr;16(2):577-594. doi: 10.1007/s12311-016-0825-6.

14.

Neuronal Nuclear Membrane Budding Occurs during a Developmental Window Modulated by Torsin Paralogs.

Tanabe LM, Liang CC, Dauer WT.

Cell Rep. 2016 Sep 20;16(12):3322-3333. doi: 10.1016/j.celrep.2016.08.044.

15.

Endolysosomal dysfunction in Parkinson's disease: Recent developments and future challenges.

Kett LR, Dauer WT.

Mov Disord. 2016 Oct;31(10):1433-1443. doi: 10.1002/mds.26797. Review.

16.

Predictive Big Data Analytics: A Study of Parkinson's Disease Using Large, Complex, Heterogeneous, Incongruent, Multi-Source and Incomplete Observations.

Dinov ID, Heavner B, Tang M, Glusman G, Chard K, Darcy M, Madduri R, Pa J, Spino C, Kesselman C, Foster I, Deutsch EW, Price ND, Van Horn JD, Ames J, Clark K, Hood L, Hampstead BM, Dauer W, Toga AW.

PLoS One. 2016 Aug 5;11(8):e0157077. doi: 10.1371/journal.pone.0157077. eCollection 2016.

17.

Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions.

Jankovic J, Bressman S, Dauer W, Kang UJ.

Mov Disord. 2015 Dec;30(14):1862-9. doi: 10.1002/mds.26445. Epub 2015 Oct 19. Review.

PMID:
26477883
18.

A novel conditional knock-in approach defines molecular and circuit effects of the DYT1 dystonia mutation.

Weisheit CE, Dauer WT.

Hum Mol Genet. 2015 Nov 15;24(22):6459-72. doi: 10.1093/hmg/ddv355. Epub 2015 Sep 14.

19.

Access of torsinA to the inner nuclear membrane is activity dependent and regulated in the endoplasmic reticulum.

Goodchild RE, Buchwalter AL, Naismith TV, Holbrook K, Billion K, Dauer WT, Liang CC, Dear ML, Hanson PI.

J Cell Sci. 2015 Aug 1;128(15):2854-65. doi: 10.1242/jcs.167452. Epub 2015 Jun 19.

20.

Forebrain deletion of the dystonia protein torsinA causes dystonic-like movements and loss of striatal cholinergic neurons.

Pappas SS, Darr K, Holley SM, Cepeda C, Mabrouk OS, Wong JM, LeWitt TM, Paudel R, Houlden H, Kennedy RT, Levine MS, Dauer WT.

Elife. 2015 Jun 8;4:e08352. doi: 10.7554/eLife.08352.

21.

α-Synuclein-independent histopathological and motor deficits in mice lacking the endolysosomal Parkinsonism protein Atp13a2.

Kett LR, Stiller B, Bernath MM, Tasset I, Blesa J, Jackson-Lewis V, Chan RB, Zhou B, Di Paolo G, Przedborski S, Cuervo AM, Dauer WT.

J Neurosci. 2015 Apr 8;35(14):5724-42. doi: 10.1523/JNEUROSCI.0632-14.2015.

22.

A novel function for the Caenorhabditis elegans torsin OOC-5 in nucleoporin localization and nuclear import.

VanGompel MJ, Nguyen KC, Hall DH, Dauer WT, Rose LS.

Mol Biol Cell. 2015 May 1;26(9):1752-63. doi: 10.1091/mbc.E14-07-1239. Epub 2015 Mar 4.

23.

Neurogenetic disease: genes, mechanisms, and future promise.

Dauer WT.

Neurotherapeutics. 2014 Oct;11(4):697-8. doi: 10.1007/s13311-014-0303-0. No abstract available.

24.

Inherited isolated dystonia: clinical genetics and gene function.

Dauer W.

Neurotherapeutics. 2014 Oct;11(4):807-16. doi: 10.1007/s13311-014-0297-7. Review.

25.

The nuclear envelope: an intriguing focal point for neurogenetic disease.

Worman HJ, Dauer WT.

Neurotherapeutics. 2014 Oct;11(4):764-72. doi: 10.1007/s13311-014-0296-8. Review.

26.

Nuclear envelope breakdown induced by herpes simplex virus type 1 involves the activity of viral fusion proteins.

Maric M, Haugo AC, Dauer W, Johnson D, Roller RJ.

Virology. 2014 Jul;460-461:128-37. doi: 10.1016/j.virol.2014.05.010. Epub 2014 Jun 2.

27.

Mouse models of neurodevelopmental disease of the basal ganglia and associated circuits.

Pappas SS, Leventhal DK, Albin RL, Dauer WT.

Curr Top Dev Biol. 2014;109:97-169. doi: 10.1016/B978-0-12-397920-9.00001-9. Review.

28.

TorsinA hypofunction causes abnormal twisting movements and sensorimotor circuit neurodegeneration.

Liang CC, Tanabe LM, Jou S, Chi F, Dauer WT.

J Clin Invest. 2014 Jul;124(7):3080-92. doi: 10.1172/JCI72830. Epub 2014 Jun 17.

29.

Author response.

Bohnen N, Sarter M, Muller M, Dauer W, Albin R.

Neurology. 2014 Apr 29;82(17):1568-9. No abstract available.

PMID:
24895748
30.

Depletion of lamina-associated polypeptide 1 from cardiomyocytes causes cardiac dysfunction in mice.

Shin JY, Le Dour C, Sera F, Iwata S, Homma S, Joseph LC, Morrow JP, Dauer WT, Worman HJ.

Nucleus. 2014 May-Jun;5(3):260-459. doi: 10.4161/nucl.29227. Epub 2014 May 23.

31.

Magic shotgun for Parkinson's disease?

Albin RL, Dauer WT.

Brain. 2014 May;137(Pt 5):1274-5. doi: 10.1093/brain/awu076. No abstract available.

PMID:
24771397
32.

Multiplying messages LRRK beneath Parkinson disease.

Dauer WT, Guo M.

Cell. 2014 Apr 10;157(2):291-293. doi: 10.1016/j.cell.2014.03.043.

33.

Lamina-associated polypeptide 1: protein interactions and tissue-selective functions.

Shin JY, Dauer WT, Worman HJ.

Semin Cell Dev Biol. 2014 May;29:164-8. doi: 10.1016/j.semcdb.2014.01.010. Epub 2014 Feb 5. Review.

34.

Parkinson's Disease: What role do pedunculopontine nucleus cholinergic neurons play?

Bohnen NI, Müller MLTM, Dauer WT, Albin RL.

Future Neurol. 2014 Jan;9(1):5-8. doi: 10.2217/fnl.13.61. Epub 2013 Dec 16. No abstract available.

35.

The nuclear envelope protein, LAP1B, is a novel protein phosphatase 1 substrate.

Santos M, Rebelo S, Van Kleeff PJ, Kim CE, Dauer WT, Fardilha M, da Cruz E Silva OA, da Cruz E Silva EF.

PLoS One. 2013 Oct 7;8(10):e76788. doi: 10.1371/journal.pone.0076788. eCollection 2013.

36.

Lamina-associated polypeptide-1 interacts with the muscular dystrophy protein emerin and is essential for skeletal muscle maintenance.

Shin JY, Méndez-López I, Wang Y, Hays AP, Tanji K, Lefkowitch JH, Schulze PC, Worman HJ, Dauer WT.

Dev Cell. 2013 Sep 30;26(6):591-603. doi: 10.1016/j.devcel.2013.08.012. Epub 2013 Sep 19.

37.

Emerging common molecular pathways for primary dystonia.

Ledoux MS, Dauer WT, Warner TT.

Mov Disord. 2013 Jun 15;28(7):968-81. doi: 10.1002/mds.25547. Review.

38.

Interplay of LRRK2 with chaperone-mediated autophagy.

Orenstein SJ, Kuo SH, Tasset I, Arias E, Koga H, Fernandez-Carasa I, Cortes E, Honig LS, Dauer W, Consiglio A, Raya A, Sulzer D, Cuervo AM.

Nat Neurosci. 2013 Apr;16(4):394-406. doi: 10.1038/nn.3350. Epub 2013 Mar 3.

39.

Parkinson syndrome. Heterogeneity of etiology; heterogeneity of pathogenesis?

Albin RL, Dauer WT.

Neurology. 2012 Jul 17;79(3):202-3. doi: 10.1212/WNL.0b013e31825dd3d0. Epub 2012 Jun 20. No abstract available.

PMID:
22722622
40.

Leucine-rich repeat kinase 2 for beginners: six key questions.

Kett LR, Dauer WT.

Cold Spring Harb Perspect Med. 2012 Mar;2(3):a009407. doi: 10.1101/cshperspect.a009407. Review.

41.

Genetic background modulates the phenotype of a mouse model of DYT1 dystonia.

Tanabe LM, Martin C, Dauer WT.

PLoS One. 2012;7(2):e32245. doi: 10.1371/journal.pone.0032245. Epub 2012 Feb 29.

42.

LRRK2 Parkinson disease mutations enhance its microtubule association.

Kett LR, Boassa D, Ho CC, Rideout HJ, Hu J, Terada M, Ellisman M, Dauer WT.

Hum Mol Genet. 2012 Feb 15;21(4):890-9. doi: 10.1093/hmg/ddr526. Epub 2011 Nov 11.

43.

Targeted disruption of neuronal 19S proteasome subunits induces the formation of ubiquitinated inclusions in the absence of cell death.

Droggiti A, Ho CC, Stefanis L, Dauer WT, Rideout HJ.

J Neurochem. 2011 Nov;119(3):630-43. doi: 10.1111/j.1471-4159.2011.07444.x. Epub 2011 Sep 28.

44.

Cerebellothalamocortical pathway abnormalities in torsinA DYT1 knock-in mice.

Uluğ AM, Vo A, Argyelan M, Tanabe L, Schiffer WK, Dewey S, Dauer WT, Eidelberg D.

Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6638-43. doi: 10.1073/pnas.1016445108. Epub 2011 Apr 4.

45.

Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design.

Martin JN, Wolken N, Brown T, Dauer WT, Ehrlich ME, Gonzalez-Alegre P.

Gene Ther. 2011 Jul;18(7):666-73. doi: 10.1038/gt.2011.10. Epub 2011 Mar 3.

46.

Contextual automated 3D analysis of subcellular organelles adapted to high-content screening.

Dorval T, Ogier A, Genovesio A, Lim HK, Kwon DY, Lee JH, Worman HJ, Dauer W, Grailhe R.

J Biomol Screen. 2010 Aug;15(7):847-57. doi: 10.1177/1087057110374993. Epub 2010 Jul 16.

PMID:
20639502
47.

A molecular mechanism underlying the neural-specific defect in torsinA mutant mice.

Kim CE, Perez A, Perkins G, Ellisman MH, Dauer WT.

Proc Natl Acad Sci U S A. 2010 May 25;107(21):9861-6. doi: 10.1073/pnas.0912877107. Epub 2010 May 10.

48.

New messages in the nuclear envelope.

Dauer WT, Worman HJ.

Cell Cycle. 2010 Feb 15;9(4):645-6. Epub 2010 Feb 15. No abstract available.

PMID:
20190576
49.

The biology and pathology of the familial Parkinson's disease protein LRRK2.

Dauer W, Ho CC.

Mov Disord. 2010;25 Suppl 1:S40-3. doi: 10.1002/mds.22717. Review.

PMID:
20187256
50.

The WD40 domain is required for LRRK2 neurotoxicity.

Jorgensen ND, Peng Y, Ho CC, Rideout HJ, Petrey D, Liu P, Dauer WT.

PLoS One. 2009 Dec 24;4(12):e8463. doi: 10.1371/journal.pone.0008463.

Supplemental Content

Support Center